Diffuse Large B Cell Lymphoma Pipeline Insight
DelveInsight’s, “Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
- Global coverage
Diffuse Large B-Cell Lymphoma Understanding
Diffuse Large B-Cell Lymphoma: Overview
Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. When you have a lymphoma, the abnormal lymphocytes build up in lymph nodes or other body organs. Each year about 5,500 people are diagnosed with DLBCL. This makes up about 40 out of 100 cases (40%) of NHL in adults. DLBCL is more common in males than females. Most people with DLBCL first notice painless lumps, often in their neck, armpit or groin. These are swollen (enlarged) lymph nodes. They usually grow quite quickly, over just a few weeks. Sometimes, DLBCL can develop in lymph nodes deep inside your body where they can’t be felt from the outside. The swollen nodes can form large lumps – known as ‘bulky disease’. DLBCL can also develop outside lymph nodes, called ‘extranodal’ disease. This affects around 1 in 5 people with DLBCL.
"Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse Large B-Cell Lymphoma pipeline landscape is provided which includes the disease overview and Diffuse Large B-Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Diffuse Large B-Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Large B-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Large B-Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.
Diffuse Large B-Cell Lymphoma Emerging Drugs Chapters
This segment of the Diffuse Large B-Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse Large B-Cell Lymphoma Emerging Drugs
Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells. CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ broad oncology collaboration. Currently, it is in phase 3 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofitamab is based on a novel structural format which we call ‘2:1’, which refers to the structure of the antibody. It is engineered to have two ‘Fab’ regions which bind to CD20, and one ‘Fab’ region which binds to CD3. A robust clinical development programme for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma, and other blood cancers.
Acalabrutinib: Acerta Pharma
Acalabrutinib is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
AUTO 3: Autolus
AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently in phase I/II stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, it is in phase 2 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
Further product details are provided in the report……..
Diffuse Large B-Cell Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse Large B-Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diffuse Large B-Cell Lymphoma
There are approx. 80+ key companies which are developing the therapies for Diffuse Large B-Cell Lymphoma. The companies which have their Diffuse Large B-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genmab.
DelveInsight’s report covers around 80+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Diffuse Large B-Cell Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Large B-Cell Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Large B-Cell Lymphoma drugs.
Diffuse Large B-Cell Lymphoma Report Insights
- Diffuse Large B-Cell Lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Diffuse Large B-Cell Lymphoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diffuse Large B-Cell Lymphoma drugs?
- How many Diffuse Large B-Cell Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Large B-Cell Lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diffuse Large B-Cell Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diffuse Large B-Cell Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?